Key Points
- Insider sale: Deepak Nath sold 1,240 shares on Nov 11 at GBX 1,257 for £15,586.80, after previously selling 18,007 shares on Aug 18 at GBX 1,351 (£243,274.57).
- Analyst sentiment is broadly positive, with three Buy and two Hold ratings creating a consensus "Moderate Buy" and an average price target of GBX 1,487.60; recent upgrades include RBC (GBX 1,700) and Citigroup (GBX 1,600).
- Stock context: Smith & Nephew has a market cap of £13.88bn and a P/E of 45.6, trading around GBX 1,266.50—below its 50‑day moving average (GBX 1,358.50) but above its 200‑day MA (GBX 1,227.41).
Smith & Nephew plc (LON:SN - Get Free Report) insider Deepak Nath sold 1,240 shares of the company's stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of GBX 1,257, for a total value of £15,586.80.
Deepak Nath also recently made the following trade(s):
- On Monday, August 18th, Deepak Nath sold 18,007 shares of Smith & Nephew stock. The shares were sold at an average price of GBX 1,351, for a total transaction of £243,274.57.
Smith & Nephew Trading Down 0.4%
Shares of Smith & Nephew stock opened at GBX 1,266.50 on Thursday. The company has a current ratio of 2.51, a quick ratio of 0.84 and a debt-to-equity ratio of 70.22. The stock has a market cap of £13.88 billion, a P/E ratio of 45.60, a P/E/G ratio of 0.46 and a beta of 0.62. The firm's 50-day moving average is GBX 1,358.50 and its two-hundred day moving average is GBX 1,227.41.
Analyst Upgrades and Downgrades
SN has been the subject of a number of research reports. Royal Bank Of Canada increased their price target on shares of Smith & Nephew from GBX 1,400 to GBX 1,700 and gave the stock an "outperform" rating in a research note on Monday, October 20th. Citigroup upped their target price on Smith & Nephew from GBX 1,450 to GBX 1,600 and gave the stock a "buy" rating in a report on Friday, October 31st. JPMorgan Chase & Co. restated an "overweight" rating on shares of Smith & Nephew in a research note on Friday, November 7th. Berenberg Bank lifted their price target on Smith & Nephew from GBX 1,100 to GBX 1,300 and gave the company a "hold" rating in a research report on Thursday, August 7th. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on Smith & Nephew from GBX 1,300 to GBX 1,400 and gave the stock a "hold" rating in a report on Wednesday, August 6th. Three equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of GBX 1,487.60.
Get Our Latest Report on Smith & Nephew
Smith & Nephew Company Profile
(
Get Free Report)
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
